Nebulized forms of<unk>  are used to treat infections that are complications of cystic fibrosis and are approved for such use in Europe and the US; they are also used off-label for non-CF bronchiectasis, ventilator-associated pneumonia, chronic obstructive pulmonary disease, mycobacterial disease, and to treat infections in people who have received lung transplants.<unk>  has strong activity against susceptible Gram-negative bacteria, including Pseudomonas aeruginosa. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. It has no useful activity against Gram-positive bacteria or anaerobes. It is known to be effective against a wide range of bacteria including Citrobacter, Enterobacter, E. coli, Haemophilus, Klebsiella, Proteus, and Serratia species. The following represents minimum inhibitory concentration (MIC) susceptibility data for a few medically significant microorganisms. * Staphylococcus aureus 8 - >128 μg/ml * Staphylococcus epidermidis 8 - 32 μg/ml * Streptococcus pyogenes 8 - ≥128 μg/ml Synergism between<unk>  and arbekacin or tobramycin against P. aeruginosa has been suggested. Spectrum of activity Acinetobacter anitratus, Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis are generally susceptible to<unk> , while some staphylococci, Staphylococcus aureus, Staphylococcus haemolyticus and Xanthomonas maltophilia are resistant to it. Furthermore, Aeromonas hydrophila, Citrobacter koseri (Citrobacter diversus), Pantoea agglomerans (Enterobacter agglomerans), Haemophilus spp. and Streptococcus pyogenes have developed resistance to<unk>  to varying degrees.<unk>  is often used in people who are penicillin allergic or who cannot tolerate aminoglycosides. Administration<unk>  is poorly absorbed when given orally, so it must be administered as an intravenous or intramuscular injection (trade name<unk> actam ), or inhaled (trade name Cayston) using an ultrasonic nebulizer. In the United States, the Food and Drug Administration (FDA) approved the inhalation form on 22 February 2010, for the suppression of P. aeruginosa infections in patients with cystic fibrosis. It received conditional approval for administration in Canada and the European Union in September 2009, and has been fully approved in Australia.
Aztreonam
Meropenem
Imipenem
Vancomycin
Cefepime
Resistin
Doripenem
Ertapenem